Agents worth testing in combination studies include FLT3 inhibitors in AML, BCR signaling inhibitors in certain NHL subtypes, and BH3 mimetic drugs (BCL2 inhibitor venetoclax and MCL-1 inhibitors) in a variety of blood cancers. The gene discussed is FLT3; the disease is acute myeloid leukemia.